POLE and cancer: In this study, we have analyzed associations between POLE proofreading mutations, recurrence-free and cancer-specific survival in two large, randomized controlled trials (PORTEC-1 and -2) (3,4) of early-stage (FIGO stage I), (high-) intermediate risk EC, with central pathology review and mature follow-up data, and in three additional smaller EC series (9,12,19).